Open AccessTreatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
Author(s) -
Ezequiel Ridruejo
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i23.7169
Subject(s) - entecavir , medicine , tenofovir , clinical practice , clinical trial , adverse effect , referral , intensive care medicine , randomized controlled trial , chronic hepatitis , family medicine , immunology , lamivudine , human immunodeficiency virus (hiv) , virus
Results from phase III clinical trials clearly demonstrate the efficacy and safety of entecavir and tenofovir in the controlled environment of randomized clinical studies. There are several studies with both drugs performed in clinical practice (also called "real life studies"). Despite the pros and cons, studies performed in real life conditions represent everyday practice and add important information about long term treatment effectiveness and safety in this clinical setting. This review shows that patients treated with first line nucleos(t)ide analogs at referral centres, with good clinical follow-up and adherence to international guidelines, can achieve high treatment response rates with a very low rate of adverse events.